Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$31.70
neg -0.33
-1.00%
Today's Range: 31.53 - 32.09 | PFE Avg Daily Volume: 28,152,100
Last Update: 01/19/17 - 3:59 PM EST
Volume: 25,964,058
YTD Performance: -1.39%
Open: $32.06
Previous Close: $32.03
52 Week Range: $28.25 - $37.39
Oustanding Shares: 6,068,355,132
Market Cap: 194,551,465,532
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 6 7
Moderate Buy 0 0 0 0
Hold 9 9 7 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.06 2.13 2.08 1.92
Latest Dividend: 0.32
Latest Dividend Yield: 3.99%
Dividend Ex-Date: 02/01/17
Price Earnings Ratio: 15.34
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
15.34 31.80 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-2.02% 3.96% 3.02%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
EBITDA 18.13B
Revenue 48.85B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $0.50 $0.62 $2.41 $2.58
Number of Analysts 8 2 9 10
High Estimate $0.54 $0.64 $2.43 $2.66
Low Estimate $0.47 $0.60 $2.38 $2.45
Prior Year $0.53 $0.67 $2.20 $2.41
Growth Rate (Year over Year) -5.42% -7.46% 9.49% 7.19%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
This small-cap biotech name could have further to run.
This small-cap biotech name could have further to run.
He's never really been a stock market guy anyway.
Animal health and oncology deal activity is heating up in 2017.
You have to think that if these stocks were so high once, then it's likely they will be again.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Disney and Goldman are doing a lot of the heavy lifting.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
None of these 10 stocks finished the year in the red.
Even among the losers, buys are scarce.

Columnist Conversations

EMN put in its third straight monthly high last week.
FIBOCALL: CSX CSX gap opening higher today, based on news. Our overshoot level @ 41.92 and I need to see a c...
Market is little changed as we are on the cusp of a presidential turnover.  Oil up a bit and seems to hav...
join me after the day of trading for a webinar talking about volume, how to analyze it and when to take it ser...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.